Tempus AI surged 9.3% in premarket trading Friday after the genetic testing firm reported a second-quarter loss per share of $0.22, better than the $0.25 loss expected by analysts. 

Revenue for the period came in at $314.6 million, ahead of the $297.8 million consensus estimate. 

Genomics revenue surged 115.3% year-on-year to $241.8 million, driven by accelerating volume growth in Oncology testing, up 26%, and Hereditary testing, up 32%.

Data and services revenue rose 35.7% to $72.8 million, supported by a 40.7% increase in Insights, the company’s data licensing business.

“The business is performing well with revenues and margins growing faster than expected, contributing to our continued improvement in adjusted EBITDA on a year-over-year basis,” said Eric Lefkofsky, Founder and CEO of Tempus.

“We saw significant re-acceleration of our clinical volumes which grew 30% in the quarter, as we delivered more than 212,000 NGS tests. Combined with our continued leadership in AI and progress toward building the largest foundation model in oncology, ‘we’re hitting our stride’ as we approach our 10th anniversary.”

For full-year 2025, Tempus now expects revenue of $1.26 billion, up from its prior forecast of $1.25 billion and above the $1.248 billion consensus.

Adjusted EBITDA is projected at $5 million, an improvement of roughly $110 million from 2024.